<SEC-DOCUMENT>0001144204-19-024512.txt : 20190508
<SEC-HEADER>0001144204-19-024512.hdr.sgml : 20190508
<ACCEPTANCE-DATETIME>20190508161554
ACCESSION NUMBER:		0001144204-19-024512
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190508
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190508
DATE AS OF CHANGE:		20190508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		19806791

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv520813_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event
reported): May 8, 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 16pt"><B>SYNTHETIC
BIOLOGICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center"><B>&nbsp;</B></TD>
    <TD STYLE="width: 34%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>001-12584</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center"><B>&nbsp;</B></TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13-3808303</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Commission File No.)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(IRS Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>9605 Medical Center Drive, Suite 270</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Rockville, MD 20850</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices
and zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: (301) 417-4364</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N/A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section
12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 38%; border: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="width: 21%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 41%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of each exchange on which registered</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock, par value $0.001 per share</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYN</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NYSE American</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 11%; text-align: left"><B>Item 2.02</B></TD><TD STYLE="text-align: justify"><B>Results of Operations and Financial Condition.</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 8, 2019, Synthetic Biologics, Inc.,
a Nevada corporation (the &ldquo;Registrant&rdquo;), issued a press release announcing its financial results for the three month
period ended March 31, 2019. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information in this Item&nbsp;2.02
and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be &ldquo;filed&rdquo;
for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of
that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item&nbsp;2.02
and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into
any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof,
regardless of any general incorporation language in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 11%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item&nbsp;9.01</B></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial Statements and Exhibits. </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d) Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following exhibit is furnished with this Current Report
on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 9%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Exhibit</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid"><B>Number</B></P></TD>
    <TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 89%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1pt solid"><B>Exhibit Description</B></P></TD></TR>
<TR>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; font-size: 10pt"><A HREF="tv520813_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><A HREF="tv520813_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release issued by Synthetic Biologics, Inc., dated May 8, 2019</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: May 8, 2019</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SYNTHETIC BIOLOGICS, INC.</B></FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 30%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="width: 15%; padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steven A. Shallcross</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Steven A. Shallcross</FONT></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">Title: Chief Executive Officer and</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">Chief Financial Officer</P></TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 15%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 80%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><A HREF="tv520813_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="tv520813_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release issued by Synthetic Biologics, Inc. dated May 8, 2019</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv520813_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right">&nbsp;&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Synthetic Biologics Reports First Quarter
2019 Operational Highlights and Financial Results</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>-- Enrollment is Ongoing in Phase
2b Investigator-Sponsored Clinical Study of SYN-010, </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>for the Treatment of IBS-C; Topline
Data Readout Anticipated in 2H 2019 --</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>-- Conference Call Today, May 8, 2019,
at 4:30 p.m. (ET) --</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><B>Rockville,
MD, May 8, 2019 &ndash;</B></FONT> <U>Synthetic Biologics, Inc.</U> <FONT STYLE="color: windowtext">(NYSE American: SYN), </FONT>a
late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients,
<FONT STYLE="color: windowtext">today provided an operational update and reported financial results for the three months ended
March 31, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.7in 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;During the first quarter, we remained
keenly focused on executing our strategy to advance our portfolio of GI and microbiome-focused clinical programs,&rdquo; stated
Steven A. Shallcross, Chief Executive &amp; Financial Officer of Synthetic Biologics. &ldquo;Enrollment into our investigator-sponsored
Phase 2b clinical trial of SYN-010 in breath methane positive irritable bowel syndrome with constipation (IBS-C) patients is ongoing
and we believe we are on track to announce a topline data-readout during the second half of 2019. Importantly, we believe dose-response
data derived from this clinical study will further fortify the already well-established clinical data set for SYN-010 and enable
regulatory discussions to potentially simplify future registration studies.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mr. Shallcross continued, &ldquo;During the first quarter, we continued to pursue our strategy for a potential
secondary clinical indication for SYN-004 (ribaxamase) in a specialized patient population which may allow for more narrow and
cost-efficient clinical development opportunities. Discussions with key opinion leaders are progressing to determine an optimal
development pathway for SYN-004 to reduce the incidence and/or severity of adverse outcomes in allogeneic hematopoietic cell transplant
(HCT) recipients. These adverse outcomes include acute graft-versus-host-disease (aGVHD) and colonization of opportunistic pathogens
such as vancomycin resistant Enterococci (VRE), each of which are associated with poor outcomes and increased mortality in allogeneic
HCT recipients. We believe SYN-004 may provide a distinct benefit to patient outcomes in allogeneic HCT recipients, where gut microbiome
damage resulting from prolonged beta-lactam antibiotic use has been linked to the development of aGVHD and colonization by VRE.
We look forward to sharing important updates and progress for this potential indication.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Clinical Development and Operational
Update</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Commenced enrollment in Phase 2b investigator-sponsored clinical study of SYN-010, for the treatment
of IBS-C</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">The Phase 2b clinical study is being conducted by the Medically Associated Science and Technology
(MAST) Program at Cedars-Sinai Medical Center and is a 12-week, placebo-controlled, double-blind, randomized clinical trial evaluating
two dose strengths of oral SYN-010 (21 mg and 42 mg) in approximately 150 patients diagnosed with IBS-C,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">The primary objective for the study will be to determine the efficacy of SYN-010, measured as an
improvement from baseline in the weekly average number of complete spontaneous bowel movements (CSBMs) during the 12-week treatment
period for SYN-010 21 mg and 42 mg daily doses relative to placebo,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Secondary efficacy endpoints for both dose strengths of SYN-010 will measure changes from baseline
in abdominal pain, bloating, stool frequency as well as the use of rescue medication relative to placebo,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">A topline data readout is anticipated in 2H 2019,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Cedars-Sinai Medical Center and Synthetic Biologics are co-funding the study. The patent rights
covering the use of SYN-010 are owned by Cedars-Sinai Medical Center and are exclusively licensed by Cedars-Sinai Medical Center
to Synthetic Biologics;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 45pt; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Continued to evaluate a potential secondary indication for SYN-004 (ribaxamase) to reduce the incidence
and/or severity of aGVHD and other adverse outcomes in allogeneic HCT recipients</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Identification of key investigators and establishment of clinical protocols are ongoing,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Anticipate initiation of a Phase 1/2 clinical study in allogeneic HCT patients in 2H 2019, contingent
upon the identification of a research partner and subsequent Institutional Review Board (IRB) approval;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Evaluated regulatory strategies to advance SYN-020 (intestinal alkaline phosphatase) to and through
clinical trials targeting areas of significant unmet medical need, including enterocolitis associated with radiation therapy for
cancer</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Submitted request for pre-IND meeting with FDA in Q1 2019,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Anticipate filing a US IND application in Q4 2019,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Plan to commence a Phase 1 clinical trial in Q1 2020;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Continued to exercise prudent cash management and financial stewardship</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">o</FONT></TD><TD STYLE="text-align: justify">Further reduced cash burn, extending projected cash runway to fund operations through at least
the end of Q2 2020;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Quarter Ended March 31, 2019 Financial
Results</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses decreased
by 30% to $1.1 million for the three months ended March 31, 2019, from $1.6 million for the three months ended March 31, 2018.
This decrease is primarily due to decreased stock-based compensation expense related to forfeitures and decreased share price,
along with the reduction of investor relations, registration, and legal costs. The charge related to stock-based compensation expense
was $65,000 for the three months ended March 31, 2019, compared to $349,000 the three months ended March 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses decreased
by 28% to $2.4 million for the three months ended March 31, 2019, from $3.4 million for the three months ended March 31, 2018.
This decrease is primarily the result of lower SYN-004 (ribaxamase) indirect program costs for the three months ended March 31,
2019, including salary and related expense reductions resulting from the 2018 restructuring and the fact that no clinical trial
activity for SYN-004 (ribaxamase) was ongoing during the quarter, offset by an increase in manufacturing costs for SYN-020. The
research and development costs incurred during the quarter were primarily related to the investigator-sponsored Phase 2b clinical
study of SYN-010. We anticipate research and development expense to increase in association with the ongoing Phase 2b investigator-sponsored
clinical study of SYN-010, a potential Phase 1/2 clinical trial of SYN-004 (ribaxamase) in allogeneic HCT recipients, and the continued
development of SYN-020. There was no charge related to stock-based compensation expense for the three months ended March 31, 2019
resulting from the 2018 restructuring, compared to $326,000 for the three months ended March 31, 2018.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other income was $44,000 for the three
months ended March 31, 2019, compared to other income of $2.7 million for the three months ended March 31, 2018. Other income
for the three months ended March 31, 2019 is primarily comprised of interest income while the three months ended March 31, 3018
is comprised of non-cash income of $2.7 million from the change in fair value of warrants. The decrease in the fair value of the
warrants was due to the decrease in our stock price.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents as of March 31,
2019 was $24.7 million, a decrease of $4.2 million from December 31, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>Conference Call</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics will hold a conference
call today, Wednesday, May 8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">, 2019,
at 4:30 p.m. (ET).</FONT> The dial-in information for the call is as follows, U.S. toll free: +1 888-347-5280 or International:
+1 412-902-4280. Participants are asked to dial in 15 minutes before the start of the call to register. The call will also be
webcast over the Internet at <U>https://www.webcaster4.com/Webcast/Page/1096/30393</U>. An archive of the call will be available
for replay at the same URL, <U>https://www.webcaster4.com/Webcast/Page/1096/30393</U><FONT STYLE="font-size: 10pt">,</FONT> for
90 days after the call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (NYSE American:
SYN) is a clinical-stage company developing therapeutics that preserve the microbiome to protect and restore the health of patients.
The Company's lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain commonly used intravenous (IV)
beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, <I>C. difficile</I> infection (CDI),
overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host-disease (aGVHD)
in allogeneic hematopoietic cell transplant (HCT) recipients, and (2) SYN-010, which is intended to reduce the impact of methane-producing
organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company
is also advancing SYN-020, an oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and
systemic diseases, and has completed proof-of-concept studies with monoclonal antibody therapies for the prevention and treatment
of pertussis. For more information, please visit Synthetic Biologics' website at <U>www.syntheticbiologics.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release contains forward-looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as &quot;may,&quot; &quot;should,&quot;
&quot;potential,&quot; &quot;continue,&quot; &quot;expects,&quot; &quot;anticipates,&quot; &quot;intends,&quot; &quot;plans,&quot;
&quot;believes,&quot; &quot;estimates,&quot; and similar expressions, and includes statements regarding <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
on track to announce a topline data- readout during the second half of 2019, <I>dose-response data derived from the investigator-sponsored
Phase 2b clinical trial of SYN-010 further fortifying the already well-established clinical data set for SYN-010 and enabling regulatory
discussions to potentially simplify future registration studies, a potential secondary clinical indication for SYN-004 (ribaxamase)
in a specialized patient population which may allow for more narrow and cost-efficient clinical development opportunities, SYN-004
providing a distinct benefit to patient outcomes in allogeneic HCT recipients, initiation of a Phase 1/2 clinical study in allogeneic
HCT patients in 2H 2019, filing of a US IND application in Q4 2019 for SYN-020, commencing a Phase 1 clinical trial for SYN-020
in Q1 2020, and extending Synthetic Biologics&rsquo; projected cash runway through at least the end of Q2 2020. These forward-looking
statements are based on management's expectations and assumptions as of the date of this press release and are subject to a number
of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current
expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause
actual results to differ materially from current expectations include, among others, the ability of Synthetic Biologics&rsquo;
product candidates to demonstrate safety and effectiveness, as well as results that are consistent with prior results, Synthetic
Biologics' clinical trials continuing enrollment as expected, a failure to receive the necessary regulatory approvals for commercialization
of Synthetic Biologics' therapeutics, including approval of proposed trial designs, a failure of Synthetic Biologics' clinical
trials, and those conducted by investigators, for SYN-004, SYN-010 and SYN-020 to be commenced or completed on time or to achieve
desired results and benefits, a failure to file INDs when anticipated, a failure of Synthetic Biologics' clinical trials to continue
enrollment as expected or receive anticipated funding, a failure of Synthetic Biologics to successfully develop, market or sell
its products, Synthetic Biologics' inability to maintain its material licensing agreements, or a failure by Synthetic Biologics
or its strategic partners to successfully commercialize products, Synthetic Biologics&rsquo; ability to achieve acceptance of its
product candidates in the marketplace and the successful development, marketing or sale of Synthetic Biologics' products by competitors
that render Synthetic Biologics' products obsolete or non-competitive, Synthetic Biologics' ability to regain compliance with the
continued listing standards of the NYSE American by September 2, 2019, Synthetic Biologics' ability to comply with other continued
listing requirements of the NYSE American, the continued maintenance and growth of Synthetic Biologics' patent estate, Synthetic
Biologics becoming and remaining profitable, Synthetic Biologics' ability to obtain or maintain the capital or grants necessary
to fund its research and development activities, a loss of any of Synthetic Biologics' key scientists or management personnel and
other factors described in Synthetic Biologics' Form 10-K for the year ended December 31, 2018 and its other filings with the SEC,
including subsequent periodic reports on Forms 10-Q and 8-K. The information in this release is provided only as of the date of
this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this release
on account of new information, future events, or otherwise, except as required by law.</I></FONT></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>For further information, please contact:</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (Corporate and
Investors)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vincent I. Perrone, Director Corporate Communication, (240)
660-2000, <U>info@syntheticbiologics.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ogilvy (Media)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gregory Kelley, Senior Vice President, (404) 836-2302, <U>gregory.kelley@ogilvy.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>- Financial Tables Follow -</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Synthetic Biologics, Inc. and Subsidiaries</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>(in thousands, except share and per share amounts)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Consolidated Balance Sheets</B></FONT> &nbsp;</P>



<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; white-space: nowrap">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">March 31, 2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid; white-space: nowrap">December 31, 2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 68%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Cash and cash equivalents</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">24,694</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">28,918</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">860</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">593</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Property and equipment, net</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">545</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">607</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 5.75pt">Right of use asset</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">510</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Deposits and other assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">23</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">23</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total Assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">26,632</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">30,141</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Liabilities and Stockholder&rsquo;s Equity</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Total liabilities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,624</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,686</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Series A Convertible Preferred Stock</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,357</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,296</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Total stockholder&rsquo;s equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,651</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,159</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Stockholders&rsquo; Equity</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">26,632</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">30,141</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Condensed Consolidated Statements of Operations</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the three months ended March 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2019</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">2018</TD><TD STYLE="padding-bottom: 1pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Operating Costs and Expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 68%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;General and administrative</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,154</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,620</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Research and development</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,418</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,370</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total Operating Costs and Expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">3,572</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,990</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Loss from Operations</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,572</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(4,990</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Other Income</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;&nbsp;&nbsp;Change in fair value of warrant liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,655</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">&nbsp;&nbsp;&nbsp;Interest income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">44</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">9</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Total Other Income</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">44</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,664</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Net Loss </B></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(3,528</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,326</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Net Loss Attributable to Non-controlling Interest</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(16</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(10</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Net Loss Attributable to Synthetic Biologics, Inc. </B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>and Subsidiaries</B></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,512</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,316</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: 4.6pt">Series A Preferred Stock Dividends</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(61</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(59</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt; text-indent: 4.6pt">Series B Preferred Stock Dividends</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(398</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; text-indent: 0.1pt">Net Loss Attributable to Common Stockholders</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(3,971</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,375</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Net Loss Per Share - Basic and Dilutive</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.25</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(0.65</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt">Weighted average number of common shares outstanding - Basic and Dilutive</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">15,656,784</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,673,340</TD><TD STYLE="padding-bottom: 2.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !1 1T# 2(  A$! Q$!_\0
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M\FI([J2:2.&%)IIII(X8884:6:::5UCBAAB16>2661ECCC0%W=E506(%</\
MVB?4_K7M'[.7B#0-+^/'PGO_ !3)#%HEOXRT[[1/=,B6MK=S)/;Z1=W+R$1Q
MP6NL2V$[R.0D03S6(5"P_P :.&^%*.>\1</9%7QE#*\/G6>Y+D];,\1%.AEU
M'-,UR[+:N.K*<Z<'3P=/&SQ$E.I3A)TH1J5:=.52I3_T"SB,\KRC-LTIX6KC
MJN6Y7F68T\%1M[;&5,#@,9C(86GRPG+GQ$\-&C%QA.2YVXPG-0A/ZQ\-_L&_
M&C7= AUG4=5\)^%KZZMUN+?P[K%QJ4^IQJ\8DCBU*;3K*XL]/N6!57@22]>W
M?<D^R161?DKQWX0\5_#3Q/?^#_&FES:1KNGB.1X#(D]O=6D^XVVH:?=Q9AO;
M"Y"MY-Q$>'22&5(KB*6)/Z3Z\E^('PI^$'Q<N6TSQUX;\.>)=8TNR6-7>58?
M$FD6-T[RPF*]L+BWUBPMI96>:!?-2WDEW.JN2V?]5/$?]GEX?8KA? T/#'.,
M;D'&&$G0ISQG%V<8K-,HXDC[*?UFGBL/A\%2J97F%25/ZQA*N34:V$I15:AB
M,OK8:$,32_A;A'Z4/$-+.L54XSRS#YED%:%6:H\/Y?0PF/R=^TA[&=*I6Q$X
M8W"04U1Q$<PJ4J\VZ52CBH5INC/^=O[=[M_G\*/MWNW^?PK]"OCA_P $^]8T
M2UO?$?P3U2\\0VMNDEQ-X&UV:$ZVL2+O== UG$$.IR ;C'IVIQV]U(%6.'4+
MJ=DA;\Q[J>[L;JYL;VWN;.]LKB6TO;*[AEMKNSN[=S'/:W5M,J36]Q!(K1S0
MRHDD;J590:_S;\2_ [C[PCS>&3\<\/U,MEB?:O+<SP\XX_(\XI4;>TJ95F^'
M@L+B73C*$J^%JQPF8853@\3@*<91K3_L?@KC#A'Q"R^>8\*YM3Q\:/(L;@JD
M/JN9Y=4J)\E/'Y?6?MZ"FU)4J\77PE=QDJ&+G*,J<?U9_84_:#FCU%/@CXJO
MGEL[N.XNOA]>74A)M+B%'N;_ ,+>8Y_X]YH5FU#1XR0(9(KRQC!66TBC_5.O
MY7='\4ZGX=UC2?$&C7,EIJ^A:E8ZQI=S&Q5H+_3KF.[M7R/X?-B4..C1ED.0
MQ%?TX?#OQE9?$+P)X1\<:=M%IXJ\/:7K<<:G<()+ZTCFN+4D\EK2X:6V?/.^
M)J_U&^@7XLYCQ7P3FOAIQ#BZF,S3P^IX*KD&*Q%253$8C@['U*F%PV!J5*DI
M5*O^KN9499?AY2E.4,JQN74'+DP5#E_C/Z4?AU0X9S_+N,,KP\:& XJGB:.9
MTJ4%&E1X@PD(8BKB(QA%0A_:N"FL55245+&X7%5$N;$5;]E1117]]'\JA111
M0!_(=_P72_X)"_M+_$S]H0_MZ_L<Z5JGC_Q%=Z9X*N/B)\._"M[%9_$[P_XQ
M^'$5G8^%OB-\-;65[=?$I.G:9H4>HZ!83_\ "1V6JZ/%JVE6>L0WUW;Z?X1^
MSW_P<U_M'_!2_LOA9^W7^S;+XTUOP^8]*USQ1X;MKSX/_%Z/[*XAN;[Q'\,_
M%]A#X<U758U4M<#2KKP39W$H+1VL);!^LOVE/^"S?Q__ &:_^"S[?LP^/OB'
M\./#'[%F@>-OAMHOCB76_!-A'J_AKP[XV^$^E:S=:YJ/CB.:34K6TT_Q?K%K
MJ,URUH8[?3 \$S+:1R3+^R_[66H?\$P_VC?@/XEU7]IWQM^S!X]^$B^&+[43
MXYU'QGX#U/5="L!:R3QZOX#\6:5J%SXCTW7X642:.?"ER=5NK]8K.UMKR6;[
M)+]+[:=/#8'#YG@(XW#U*$)X2MAW46(I4IM)4^:,.64XIK]W=-KE^+21X7LX
MSKXNM@,6\+5A5E'$4JR@Z-2I!7<^64KJ#L_?2LGS?#K$\7_92L/^"5__  4*
M\(_'/X[_ ++G@SP#I_Q$^-'A+XA_#7X]>+=&\(Z7X+_:&\,_\+FT6ZL?%MMX
MTMKZUOKJPU7Q!;E]1L]8>+6O#>N7FGFZL+[6([*[1/X:?VP?V%OAI^Q/_P %
M#[S]D_XN7_BL_L]6?Q ^'+CQY8IH<7CR\_9[^(4^F*WBJTOY=%;0)?%'ANQN
M-;T_4KE=$.FRZQX:OV338TD6V3] /^#;;4?%MA_P5 O]+^'=SKUS\.=5^#/Q
MAA\=/)%(D=WX%TO5]'G^'>I>*(518K?41XB?0EM6F2*2&^U+4[:W"+/<QM^I
M/_!TW^R>GB?X6?!+]L70--\V_P#AOK$_P5^)\\,;-)+X$\?7$FH>"=2NRB_+
M;:!XVBO=($LC863QTJY4#-=N&;RS.'@/K%6>'QE""INI/FJT:DJ<UATY/FM.
MGRRIPVCRRA^[33ORUTL=EBQGL*<:V&JR<U"/+"K!3@ZSLK7C/FC.6[NI^^[J
MWY[?\'('[,W[-WP!\;?LCW/@3Q#XNU[XH:I\!O#'PVO=.\0:GX>U3PYI_P "
M_@!X>L/!G@#Q($L/#^GWA\3^)=1U&ZCO=06_;1[Z/1M2ELM*L-J _J;_ ,$P
M/^")7PMU;_@F9XUT#XR>(OB5X<\5?\%"?AE\*O$GQ4TSP]<>&-.3P+X;\*^,
M;GXD_"FS\*VVH>&-2:+5Y]*O-&N?%TNO'5$N9KJZL+"TTHP+<-_-U\(Y_BE_
MP5U_;W_8X^%'Q%:\U&WT[P/\%_@MXFGBG>Y>#X-_ /P])J_Q'\3W+OM2"_\
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M^$-8^&]SHWAF#PIHMIJGCV31YKK3M9M[,>([B>*+P+:2QK>W4D327UQO3;'
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M(89T,'1H^]%T^2;5.G"G.,U*2234FN;X7\3;<F[:_E+_ ,&L'[*4C/\ 'O\
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M7:R:]J@?6=<C;J28M5U"\B!)Y5!C P!\C_$_X./^T1^WEX*O-3LS-\-?V;/
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M8U/95OJV.P]7#5_95>6?LZGLJL^2?)/DE:7+*UG[G#'$.8<)<29!Q5E'U?\
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, !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
